非ウイルス薬物デリバリーシステムの世界市場レポート2025年

非ウイルス薬物デリバリーシステムの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.2％で167億2,000万米ドルに成長します。予測期間の成長を牽引するのは、標的治療の採用拡大、ドラッグデリバリー革新への投資拡大、非侵襲的治療法への関心の高まり、人工知能の統合強化、徐放性製剤へのニーズの高まりなどです。この期間に予想される主な動向には、ナノキャリア技術の進歩、次世代バイオマテリアルの開発、mRNAデリバリーシステムの革新、スマートドラッグデリバリーデバイスの組み込み、遺伝子編集デリバリー技術の改善などがあります。

個別化医療に対する需要の高まりは、非ウイルス薬物デリバリーシステム市場の成長を促進すると予想されます。個別化医療とは、個人の遺伝子プロファイル、ライフスタイル、環境要因に合わせた治療アプローチです。この需要の高まりは、各患者の疾患の根本原因に対処する、より効果的な治療の可能性によって後押しされています。非ウイルス性システムは、薬物や遺伝子を細胞に安全に送達することにより、リスクを最小限に抑え、治療の精度を高めることで、個別化医療をサポートします。例えば、2024年2月、米国を拠点とする非営利団体である個別化医療連合（Personalized Medicine Coalition）は、FDAが2023年に希少疾患患者を対象とした新たな個別化治療を16件承認し、2022年の6件から増加したと報告しました。その結果、個別化医薬品への嗜好の高まりが非ウイルス薬物デリバリーシステム市場の拡大に寄与しています。

非ウイルス性ドラッグデリバリーシステム市場の主な企業は、RNAベースの治療法の開発と市場開拓を促進するために、あらかじめ最適化されたイオン化可能な脂質混合システムなどの先進技術の使用を重視しています。この製剤技術により、RNA分子を脂質ナノ粒子内に効率的にカプセル化し、安定性、ペイロード保護、標的遺伝子送達を確保することができます。例えば、米国を拠点とするバイオテクノロジー企業Cytiva社は2024年9月、同社のNanoAssemblr IgniteおよびIgnite+プラットフォームと互換性のあるRNAデリバリーLNPキットを発表しました。このシステムは、すぐに使用できるイオン化可能な脂質ミックスを特徴としており、迅速なRNAペイロードのスクリーニングとデリバリーの検証が可能で、特に感染症のワクチン開発に有用です。自動マイクロ流体プラットフォームと統合し、GMPグレードの材料を用いたスケーラブルな製造をサポートし、創薬から臨床試験までユーザーを導くプロトコールと概念実証データを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の非ウイルス薬物デリバリーシステム：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の非ウイルス薬物デリバリーシステム市場：成長率分析
• 世界の非ウイルス薬物デリバリーシステム市場の実績：規模と成長, 2019-2024
• 世界の非ウイルス薬物デリバリーシステム市場の予測：規模と成長, 2024-2029, 2034F
• 世界の非ウイルス薬物デリバリーシステム：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の非ウイルス薬物デリバリーシステム市場送達される分子の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• 小分子
• 世界の非ウイルス薬物デリバリーシステム市場投与される生物学的製剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リボ核酸（RNA）
• デオキシリボ核酸（DNA）
• タンパク質またはペプチド
• 抗体
• 世界の非ウイルス薬物デリバリーシステム市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製薬およびバイオテクノロジー企業
• 学術研究機関
• 契約開発製造組織（CDMO）
• 病院と診療所
• 世界の非ウイルス薬物デリバリーシステム市場、生物製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペプチド
• タンパク質
• モノクローナル抗体
• RNAベースの治療薬
• DNAベースの治療法
• 世界の非ウイルス薬物デリバリーシステム市場、小分子のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法薬
• 抗炎症薬
• 抗ウイルス薬
• 抗生物質
• ホルモン薬

第7章 地域別・国別分析

• 世界の非ウイルス薬物デリバリーシステム市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非ウイルス薬物デリバリーシステム市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非ウイルス薬物デリバリーシステム市場：競合情勢
• 非ウイルス薬物デリバリーシステム市場：企業プロファイル
  • Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • Cytiva Overview, Products and Services, Strategy and Financial Analysis
  • Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • CureVac N.V. Overview, Products and Services, Strategy and Financial Analysis
  • PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ethris GmbH
• Entos Pharmaceuticals Inc.
• Liquidia Technologies Inc.
• ReCode Therapeutics Inc.
• Enable Injections Inc.
• GenEdit Inc.
• N4 Pharma Plc
• Hopewell Therapeutics Inc.
• Tiba Biotech LLC
• Vesigen Therapeutics Inc.
• Carmine Therapeutics Inc.
• Evox Therapeutics Ltd
• InnoCore Pharmaceuticals BV
• Nanomerics Ltd
• DelSiTech Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非ウイルス薬物デリバリーシステム市場2029：新たな機会を提供する国
• 非ウイルス薬物デリバリーシステム市場2029：新たな機会を提供するセグメント
• 非ウイルス薬物デリバリーシステム市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-viral drug delivery systems are methods used to administer therapeutic agents into the body without relying on viral vectors. These systems utilize various physical, chemical, or mechanical approaches-such as nanoparticles, liposomes, or polymer-based carriers-to effectively transport drugs to specific target areas. Their primary goal is to minimize the risks commonly associated with viral delivery methods, including immune responses and insertional mutagenesis. This strategy improves the overall efficacy of treatments while enhancing patient safety for a wide range of medical conditions.

Non-viral drug delivery systems are primarily used to deliver two main categories of molecules: biologics and small molecules. Biologics are therapeutic agents derived from living organisms and include proteins, peptides, monoclonal antibodies, as well as nucleic acid-based treatments like RNA and DNA. The biologics delivered using these systems include ribonucleic acid (RNA), deoxyribonucleic acid (DNA), proteins or peptides, and antibodies. The major end users of these systems are pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), and hospitals and clinics.

The non-viral drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides non-viral drug delivery systems market statistics, including the non-viral drug delivery systems industry global market size, regional shares, competitors with the non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends, and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $8.60 billion in 2024 to $9.84 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth during the historical period is due to various drivers such as the increasing demand for safer gene therapy options, advancements in nanotechnology, a higher prevalence of chronic diseases, a stronger focus on personalized medicine, and enhanced regulatory backing for non-viral platforms.

The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $16.72 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. Growth in the forecast period will be driven by the increasing adoption of targeted therapies, greater investment in drug delivery innovation, rising interest in non-invasive treatment methods, enhanced integration of artificial intelligence, and the growing need for sustained-release drug formulations. Key trends anticipated during this period include progress in nanocarrier technologies, development of next-generation biomaterials, innovations in mRNA delivery systems, incorporation of smart drug delivery devices, and improvements in gene editing delivery techniques.

The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market. Personalized medicine is a treatment approach tailored to an individual's genetic profile, lifestyle, and environmental factors. This growing demand is fueled by the potential for more effective treatments that address the root causes of disease in each patient. Non-viral systems support personalized medicine by delivering drugs or genes safely to cells, thereby minimizing risks and enhancing treatment accuracy. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, up from six approvals in 2022. As a result, the increasing preference for personalized medicines is contributing to the expansion of the non-viral drug delivery systems market.

Key companies in the non-viral drug delivery system market are emphasizing the use of advanced technologies, such as pre-optimized ionizable lipid mix systems, to facilitate the development and delivery of RNA-based therapies. This formulation technology allows RNA molecules to be efficiently encapsulated within lipid nanoparticles, ensuring stability, payload protection, and targeted gene delivery. For instance, in September 2024, Cytiva, a U.S.-based biotechnology firm, introduced an RNA delivery LNP kit that is compatible with its NanoAssemblr Ignite and Ignite+ platforms. The system features a ready-to-use ionizable lipid mix that enables swift RNA payload screening and validation for delivery, particularly useful in vaccine development for infectious diseases. It integrates with automated microfluidic platforms, supports scalable manufacturing using GMP-grade materials, and provides protocols and proof-of-concept data to guide users from discovery through clinical trials.

In September 2023, SOHM Inc., a U.S.-based pharmaceutical firm, acquired ABBIE from CGA 369 for $10 million to enhance its non-viral gene-editing capabilities. This acquisition bolsters SOHM's ability to deliver large genetic payloads through integrase-based, non-viral platforms. ABBIE is being developed for off-the-shelf gene-editing kits, with plans for commercialization in 2024 and human trials expected by the end of 2025. CGA 369, also a U.S.-based biotechnology company, focuses on non-viral, integrase-driven gene-editing and genetic delivery solutions.

Major players in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, and Curapath Inc.

North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Drug Delivery Systems Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-viral drug delivery systems market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Molecule Delivered: Biologics; Small Molecules
• 2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA); Proteins or Peptides; Antibodies
• 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Development And Manufacturing Organizations (CDMOs); Hospitals And Clinics
• Subsegments:
• 1) By Biologics: Peptides; Proteins; Monoclonal Antibodies; RNA-based Therapeutics; DNA-based Therapies
• 2) By Small Molecules: Chemotherapeutics; Anti-inflammatories; Antivirals; Antibiotics; Hormonal Drugs
• Companies Mentioned: Evonik Industries AG; Cytiva; Arcturus Therapeutics Holdings Inc.; CureVac N.V.; PolyPid Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Viral Drug Delivery Systems Market Characteristics

3. Non-Viral Drug Delivery Systems Market Trends And Strategies

4. Non-Viral Drug Delivery Systems Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Non-Viral Drug Delivery Systems Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Viral Drug Delivery Systems PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Viral Drug Delivery Systems Market Growth Rate Analysis
• 5.4. Global Non-Viral Drug Delivery Systems Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Viral Drug Delivery Systems Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Viral Drug Delivery Systems Total Addressable Market (TAM)

6. Non-Viral Drug Delivery Systems Market Segmentation

• 6.1. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Small Molecules
• 6.2. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ribonucleic Acid (RNA)
• Deoxyribonucleic Acid (DNA)
• Proteins Or Peptides
• Antibodies
• 6.3. Global Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical And Biotechnology Companies
• Academic And Research Institutes
• Contract Development And Manufacturing Organizations (CDMOs)
• Hospitals And Clinics
• 6.4. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptides
• Proteins
• Monoclonal antibodies
• RNA-based therapeutics
• DNA-based therapies
• 6.5. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapeutics
• Anti-inflammatories
• Antivirals
• Antibiotics
• Hormonal drugs

7. Non-Viral Drug Delivery Systems Market Regional And Country Analysis

• 7.1. Global Non-Viral Drug Delivery Systems Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Viral Drug Delivery Systems Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Viral Drug Delivery Systems Market

• 8.1. Asia-Pacific Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Viral Drug Delivery Systems Market

• 9.1. China Non-Viral Drug Delivery Systems Market Overview
• 9.2. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Viral Drug Delivery Systems Market

• 10.1. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Viral Drug Delivery Systems Market

• 11.1. Japan Non-Viral Drug Delivery Systems Market Overview
• 11.2. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Viral Drug Delivery Systems Market

• 12.1. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Viral Drug Delivery Systems Market

• 13.1. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Viral Drug Delivery Systems Market

• 14.1. South Korea Non-Viral Drug Delivery Systems Market Overview
• 14.2. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Viral Drug Delivery Systems Market

• 15.1. Western Europe Non-Viral Drug Delivery Systems Market Overview
• 15.2. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Viral Drug Delivery Systems Market

• 16.1. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Viral Drug Delivery Systems Market

• 17.1. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Viral Drug Delivery Systems Market

• 18.1. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Viral Drug Delivery Systems Market

• 19.1. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Viral Drug Delivery Systems Market

• 20.1. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Viral Drug Delivery Systems Market

• 21.1. Eastern Europe Non-Viral Drug Delivery Systems Market Overview
• 21.2. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Viral Drug Delivery Systems Market

• 22.1. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Viral Drug Delivery Systems Market

• 23.1. North America Non-Viral Drug Delivery Systems Market Overview
• 23.2. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Viral Drug Delivery Systems Market

• 24.1. USA Non-Viral Drug Delivery Systems Market Overview
• 24.2. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Viral Drug Delivery Systems Market

• 25.1. Canada Non-Viral Drug Delivery Systems Market Overview
• 25.2. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Viral Drug Delivery Systems Market

• 26.1. South America Non-Viral Drug Delivery Systems Market Overview
• 26.2. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Viral Drug Delivery Systems Market

• 27.1. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Viral Drug Delivery Systems Market

• 28.1. Middle East Non-Viral Drug Delivery Systems Market Overview
• 28.2. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Viral Drug Delivery Systems Market

• 29.1. Africa Non-Viral Drug Delivery Systems Market Overview
• 29.2. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Viral Drug Delivery Systems Market Competitive Landscape And Company Profiles

• 30.1. Non-Viral Drug Delivery Systems Market Competitive Landscape
• 30.2. Non-Viral Drug Delivery Systems Market Company Profiles
  • 30.2.1. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Cytiva Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. CureVac N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Non-Viral Drug Delivery Systems Market Other Major And Innovative Companies

• 31.1. Ethris GmbH
• 31.2. Entos Pharmaceuticals Inc.
• 31.3. Liquidia Technologies Inc.
• 31.4. ReCode Therapeutics Inc.
• 31.5. Enable Injections Inc.
• 31.6. GenEdit Inc.
• 31.7. N4 Pharma Plc
• 31.8. Hopewell Therapeutics Inc.
• 31.9. Tiba Biotech LLC
• 31.10. Vesigen Therapeutics Inc.
• 31.11. Carmine Therapeutics Inc.
• 31.12. Evox Therapeutics Ltd
• 31.13. InnoCore Pharmaceuticals BV
• 31.14. Nanomerics Ltd
• 31.15. DelSiTech Ltd

32. Global Non-Viral Drug Delivery Systems Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Viral Drug Delivery Systems Market

34. Recent Developments In The Non-Viral Drug Delivery Systems Market

35. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies

• 35.1 Non-Viral Drug Delivery Systems Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Viral Drug Delivery Systems Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Viral Drug Delivery Systems Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer